VIR

VIR

USD

Vir Biotechnology Inc. Common Stock

$5.250-0.210 (-3.846%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$5.460

High

$5.520

Low

$5.200

Volume

1.66M

Company Fundamentals

Market Cap

729.3M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

1.44M

Exchange

NMS

Currency

USD

52-Week Range

Low $4.155Current $5.250High $14.45

Related News

BusinessWire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will

View more
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
BusinessWire

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical trial builds on

View more
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
BusinessWire

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to showcase progress in

View more
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025